Category Archives: drug design
Caught Our Notice: Forged email for corresponding author dooms diabetes paper
Title: Naringin Alleviates Diabetic Kidney Disease through Inhibiting Oxidative Stress and Inflammatory Reaction What Caught Our Attention: PLOS ONE had a few reasons for retracting a 2015 paper about a treatment for kidney disease due to diabetes: For one, despite what the paper claims, the authors did not obtain ethical approval to conduct the reported … Continue reading Caught Our Notice: Forged email for corresponding author dooms diabetes paper
PNAS wouldn’t let authors cite unpublished manuscript. Now, it admits it was wrong.
Question: Do you value Retraction Watch? If so, would you consider a tax-deductible donation of $25, or a recurring donation of an amount of your choosing, to support us? When researchers submitted a paper about a type of microparticle to PNAS, they wanted to give credit where it was due, and cite an unpublished manuscript … Continue reading PNAS wouldn’t let authors cite unpublished manuscript. Now, it admits it was wrong.
Posted by in drug design, engineering, freely available, japan retractions, NAS, PNAS, reference problems, spain
Ethics, authorship concerns sink homeopathy paper by researchers arrested last year
For a host of reasons, a journal has retracted a paper co-authored by a researcher who reportedly once faced charges of practicing medicine without proper qualifications. According to the retraction notice for “Psorinum Therapy in Treating Stomach, Gall Bladder, Pancreatic, and Liver Cancers: A Prospective Clinical Study,” published Dec. 8, 2010 in Evidence-Based Complementary and … Continue reading Ethics, authorship concerns sink homeopathy paper by researchers arrested last year
Child took wrong compound for over a year after “communication error”
A journal is retracting a paper after it discovered researchers gave a child the wrong supplement for more than a year. Rhiannon Bugno, managing editor for Biological Psychiatry, told Retraction Watch the mix-up did not put the patient at risk. However, the mistake was enough for the journal’s editor, John Krystal, of Yale University, to … Continue reading Child took wrong compound for over a year after “communication error”
A “GROSS CASE OF PLAGIARISM:” How did one Elsevier journal plagiarize another?
When Nicholas Peppas, chair of engineering at the University of Texas at Austin, discovered one of his papers had been plagiarized, he decided to “go public!” On February 27, Peppas tweeted about a “gross case of plagiarism:” He alleged a 2013 review published in Saudi Pharmaceutical Journal had directly copied sections of his 2011 review … Continue reading A “GROSS CASE OF PLAGIARISM:” How did one Elsevier journal plagiarize another?
Posted by in Adv Drug Delivery Rev, drug design, elsevier, india retractions, plagiarism, Saudi Pharm J, united states
Journal retracts letter for missing disclosure author says he tried to submit
An emergency medicine journal has retracted a letter to the editor, saying it didn’t include the author’s relevant commercial interest—which the author says he tried to disclose when he submitted the paper. The author, Guy Weinberg, told Retraction Watch he had noted his conflict of interest when he submitted the letter last March, but said […]
The post Journal retracts letter for missing disclosure author says he tried to submit appeared first on Retraction Watch.
Lancet retracts and replaces news story about controversial abortion drug
The Lancet has retracted a journalist-written piece about a controversial drug used off-label to induce abortions, and replaced it with a corrected version. In the retraction notice, the journal said it “removed the information that we believe to be inaccurate.” The article, first published Oct. 28, 2017, highlights Pfizer’s decision to withdraw the drug, misoprostol, […]
The post Lancet retracts and replaces news story about controversial abortion drug appeared first on Retraction Watch.
Posted by in drug design, elsevier, erroneous data, freely available, lancet, retract and replace
Dispute over author order torpedoes paper on syndrome linked to autism
At least one disgruntled co-author has triggered the retraction of a paper presenting a novel approach to treating a rare, genetically inherited condition. The paper concerned research on Fragile X syndrome (FXS), characterized by both intellectual and physical abnormalities, which is linked autism. A compound that passed through phase 2 clinical trials in October 2015 […]
The post Dispute over author order torpedoes paper on syndrome linked to autism appeared first on Retraction Watch.
Released FDA docs reveal details of agency’s (failed) attempt to retract paper
Earlier this year, a raging controversy regarding a new drug spilled into the pages of a leading medical journal: the head of the U.S. Food and Drug Administration and another official publicly called for the retraction or correction of a peer-reviewed article about the drug. They didn’t get their wish. Now, documents released by the […]
The post Released FDA docs reveal details of agency’s (failed) attempt to retract paper appeared first on Retraction Watch.
Posted by in Annals of Neurology, disputed data, drug design, united states, wiley
PLOS ONE retracts paper after researcher admits to fabricating data
On June 19, 2017, the U.S. Office of Research Integrity published its first misconduct finding of the year. The ORI reported that Brandi M. Baughman — a former research training awardee at the National Institute of Environmental and Health Sciences (NIEHS) — had “falsified and/or fabricated data” in 11 figures in a 2016 paper published in PLOS […]
The post PLOS ONE retracts paper after researcher admits to fabricating data appeared first on Retraction Watch.
Posted by in drug design, faked data, freely available, image manipulation, ori investigations, PLoS, PLOS One, united states